Clinical Sites h1 >
Cedars Sinai Medical Center
Duke University Medical Center
Durham, North Carolina 27710-1000
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
8202: Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis (ADAPT-teleMG)
The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis is a pilot study designed to better understand the use of modified clinical assessments during telehealth visits for patients with Myasthenia Gravis. A total of 50 adult participants with confirmed diagnosis of MG, with a range of disease severity will be enrolled across sites.
George Washington University - Administrative Core
Washington, District of Columbia 20037
Recruiting
8203: Genome Wide Association Study for Muscle Specific Kinase Myasthenia Gravis
Study personnel will perform broad outreach via social media, patient advocacy groups, academic institutions to identify subjects with MUSK myasthenia who will be willing to provide verification of laboratory diagnosis, medical and family history, and a saliva sample. Subjects will be able to contact the study personnel by website, email, phone, and mail. Once inclusion criteria are met, saliva collection kit will be mailed with a return mailer. Samples will be stored in the GW biorepository until the study is complete. Saliva will then be shipped to NIH after an appropriate material transfer agreement is approved.
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
8202: Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis (ADAPT-teleMG)
The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis is a pilot study designed to better understand the use of modified clinical assessments during telehealth visits for patients with Myasthenia Gravis. A total of 50 adult participants with confirmed diagnosis of MG, with a range of disease severity will be enrolled across sites.
Massachusetts General Hospital
Boston, Massachusetts 02114
Closed
8202: Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis (ADAPT-teleMG)
The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis is a pilot study designed to better understand the use of modified clinical assessments during telehealth visits for patients with Myasthenia Gravis. A total of 50 adult participants with confirmed diagnosis of MG, with a range of disease severity will be enrolled across sites.
Medical University of South Carolina
Charleston, South Carolina 29464
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
University of California Irvine
Orange, California 92868
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
University of Chicago
Chicago, Illinois 60637
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
8202: Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis (ADAPT-teleMG)
The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis is a pilot study designed to better understand the use of modified clinical assessments during telehealth visits for patients with Myasthenia Gravis. A total of 50 adult participants with confirmed diagnosis of MG, with a range of disease severity will be enrolled across sites.
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 27599-7025
There are no studies at this time
Wake Forest School of Medicine
Winston-Salem, North Carolina 27157
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
Yale School of Medicine
New Haven, Connecticut 06510
Closed
8201: Explore MG 2
Designed to better understand disease characteristics and identify treatment predictive and responsive biomarkers for myasthenia gravis. A total of 300-400 participants with confirmed diagnosis of myasthenia gravis are expected to be enrolled in the study.
8202: Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis (ADAPT-teleMG)
The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis is a pilot study designed to better understand the use of modified clinical assessments during telehealth visits for patients with Myasthenia Gravis. A total of 50 adult participants with confirmed diagnosis of MG, with a range of disease severity will be enrolled across sites.